All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Treating classical Hodgkin lymphoma: Spotlight on targeted therapies

with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce

Saturday, November 2, 2024
8:50-9:50 CET

Register now

This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.

  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2017-01-24T21:29:45.000Z

ELN Recommendations 2017 on Diagnosis and Management of Acute Myeloid Leukemia in Adults – Comments from Clara D. Bloomfield, co-author of the paper published in Blood*

Jan 24, 2017
Share:

Clara D. Bloomfield, MD, worldwide-recognized expert in AML was interviewed to provide her expert opinions on the new ELN recommendations. The transcripts are found below.

Why was it important to publish new European LeukemiaNet (ELN) recommendations on the Diagnosis and Management of Acute Myeloid Leukemia (AML)?

Was it specifically because of the new category “myeloid neoplasms with germline predisposition” in the new WHO classification?

Table 1: WHO classification of “myeloid neoplasms with germline predisposition” and guide for molecular genetic diagnostics

What are the new diagnostic procedure recommendations and when is molecular genetic testing included in the new diagnostic workup?

Table 2: 2017 European LeukemiaNet risk stratification by genetics

Which technique will be used to assess response: RT-qPCR (Real-Time Quantitative Polymerase Chain Reaction) or MFC (Multiparameter Flow Cytometry)?

You have included a new response criterion: CRMRD.?

Table 3: Response criteria in Acute Myeloid Leukemia

Will it be easy for hospitals to use this new response criterion?

You have established a new response criterion: “Progressive Disease”; can you explain why?

  1. * Döhner H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016: DOI:10.1182/blood-2016-08-733196.

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
11 votes - 11 days left ...

Related articles

Newsletter

Subscribe to get the best content related to AML delivered to your inbox